Protein Summary
Plays a role in the normal development of the peripheral and central nervous system. The protein encoded by this gene is a member of the WD-repeat family of regulatory proteins and may be involved in normal development of the peripheral and central nervous system. The encoded protein is part of the nuclear pore complex and is anchored there by NDC1. Defects in this gene are a cause of achalasia-addisonianism-alacrima syndrome (AAAS), also called triple-A syndrome or Allgrove syndrome. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2010]
- ENST00000209873
- ENSP00000209873
- ENSG00000094914
- ENST00000394384
- ENSP00000377908
- ADRACALA
- AAA
- AAASb
- GL003
- ALADIN
- ADRACALA
- ADRACALIN
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
pathway | 0.99 | ||
transcription factor binding site profile | 0.95 | ||
cellular component | 0.75 | ||
biological process | 0.74 | ||
small molecule perturbation | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 163.58 (req: < 5)
Gene RIFs: 34 (req: <= 3)
Antibodies: 221 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 163.58 (req: >= 5)
Gene RIFs: 34 (req: > 3)
Antibodies: 221 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0